Company Filing History:
Years Active: 2019-2020
Title: Aureliano Gaiassi: Innovator in Polypeptide Analysis
Introduction
Aureliano Gaiassi is a notable inventor based in Cinisello Balsamo, Italy. He has made significant contributions to the field of polypeptide analysis, holding two patents that enhance the understanding and characterization of complex polypeptide mixtures. His work is particularly relevant in pharmaceutical applications, where precision and accuracy are paramount.
Latest Patents
Gaiassi's latest patents include innovative methods for analyzing polypeptide mixtures. The first patent, titled "RP-HPLC analysis of complex polypeptide mixtures," focuses on reversed phase high-performance liquid chromatography (HPLC) methods. This invention is designed to characterize glatiramer acetate and similar polypeptide mixtures, distinguishing glatiramer acetate from non-conforming copolymers. This method is crucial for selecting batches of glatiramer acetate that are suitable for pharmaceutical use. The second patent, "Analysis of the molecular weight distribution of complex polypeptide mixtures," introduces simple size exclusion chromatography (SEC) analytical methods. This invention allows for the assessment of accurate molecular weight distributions of certain polypeptide mixtures known as glatiramoids, providing an absolute molecular weight distribution profile.
Career Highlights
Aureliano Gaiassi is associated with Chemi S.p.a., where he applies his expertise in polypeptide analysis. His work has contributed to advancements in the pharmaceutical industry, particularly in the characterization of complex polypeptides. Gaiassi's innovative approaches have positioned him as a key figure in his field.
Collaborations
Gaiassi collaborates with talented professionals such as Andrea Stevenazzi and Maria Lattanzio. Their combined efforts contribute to the ongoing research and development in polypeptide analysis.
Conclusion
Aureliano Gaiassi is a distinguished inventor whose work in polypeptide analysis has significant implications for the pharmaceutical industry. His patents reflect a commitment to innovation and precision in the characterization of complex polypeptide mixtures.